However, the main mechanism of this inhibitor is binding to Mcl-1 as a supplemental therapy in Bcl-xLlow or Bcl-xL− cancer cells or cells with resistance to Bcl-2 inhibitors [38]. The gene discussed is BCL2; the disease is cancer.